Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues
Jason Wallach, Heather Kang, Tristan Colestock, et al.
PLoS ONE (2016) Vol. 11, Iss. 6, pp. e0157021-e0157021
Open Access | Times Cited: 61

Showing 26-50 of 61 citing articles:

Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist properties
Heather Kang, Pojeong Park, Zuner A. Bortolotto, et al.
Neuropharmacology (2016) Vol. 112, pp. 144-149
Open Access | Times Cited: 24
When good times go bad: managing ‘legal high’ complications in the emergency department
Charles Caffrey, Patrick M. Lank
Open Access Emergency Medicine (2017) Vol. Volume 10, pp. 9-23
Open Access | Times Cited: 21
Analytically diagnosed intoxication by 2-methoxphenidine and flubromazepam mimicking an ischemic cerebral disease
A. Valli, Davide Lonati, C. Locatelli, et al.
Clinical Toxicology (2017) Vol. 55, Iss. 6, pp. 611-612
Closed Access | Times Cited: 19
Engineering molecularly imprinted polymers (MIPs) for the selective extraction and quantification of the novel psychoactive substance (NPS) methoxphenidine and its regioisomers
Joseph W. Lowdon, Soliman Mohamed Omar Alkirkit, Ryan E. Mewis, et al.
The Analyst (2018) Vol. 143, Iss. 9, pp. 2002-2007
Open Access | Times Cited: 19
Mechanistic Insights into the Stimulant Properties of Novel Psychoactive Substances (NPS) and Their Discrimination by the Dopamine Transporter—In Silico and In Vitro Exploration of Dissociative Diarylethylamines
Michelle A. Sahai, Colin Davidson, Neelakshi Dutta, et al.
Brain Sciences (2018) Vol. 8, Iss. 4, pp. 63-63
Open Access | Times Cited: 16
The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia
Jinwei Xu, Yaohao Li, Biqing Tian, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 8
Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4‐[1‐(3‐methoxyphenyl)cyclohexyl]morpholine (3‐MeO‐PCMo) and analogues
Tristan Colestock, Jason Wallach, Matt Mansi, et al.
Drug Testing and Analysis (2017) Vol. 10, Iss. 2, pp. 272-283
Open Access | Times Cited: 13
Minireview: Animal model of schizophrenia from the perspective of behavioral pharmacology: Effect of treatment on cognitive functions
Karel Valeš, Kristína Holubová
Neuroscience Letters (2021) Vol. 761, pp. 136098-136098
Closed Access | Times Cited: 11
A structural spectroscopic study of dissociative anaesthetic methoxphenidine
Bronislav Jurásek, Patrik Fagan, Bohumil Dolenský, et al.
New Journal of Chemistry (2023) Vol. 47, Iss. 9, pp. 4543-4551
Open Access | Times Cited: 4
Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model
Cailian Lu, Shan Li, Lin Kang, et al.
Neuroscience Letters (2023) Vol. 812, pp. 137410-137410
Closed Access | Times Cited: 4
New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
Fabrizio Schifano, Flavia Napoletano, Stefania Chiappini, et al.
Current Addiction Reports (2019) Vol. 6, Iss. 2, pp. 140-152
Open Access | Times Cited: 11
Synthesis and identification of deschloroketamine metabolites in rats' urine and a quantification method for deschloroketamine and metabolites in rats' serum and brain tissue using liquid chromatography tandem mass spectrometry
Kateřina Hájková, Bronislav Jurásek, Jan Čejka, et al.
Drug Testing and Analysis (2019) Vol. 12, Iss. 3, pp. 343-360
Closed Access | Times Cited: 11
Application and assessment of deep learning for the generation of potential NMDA receptor antagonists
Katherine Schultz, Sean Colby, Yasemin Yesiltepe, et al.
Physical Chemistry Chemical Physics (2020) Vol. 23, Iss. 2, pp. 1197-1214
Open Access | Times Cited: 11
Identification and quantification of diphenidine in hair by LC-MS/MS after single administration
Jean‐Claude Alvarez, Nicolas Fabresse, A. Knapp, et al.
Annales de Toxicologie Analytique (2016) Vol. 29, Iss. 1, pp. 64-70
Closed Access | Times Cited: 9
Assessment of the rapid and sustained antidepressant-like effects of dextromethorphan in mice
Jesus S. Saavedra, Patrick I. Garrett, Sarah C. Honeycutt, et al.
Pharmacology Biochemistry and Behavior (2020) Vol. 197, pp. 173003-173003
Closed Access | Times Cited: 9
Severe Serotonin Syndrome in an Autistic New Psychoactive Substance User After Consumption of Pills Containing Methoxphenidine and α-Methyltryptamine
Basile Chrétien, Joanna Bourgine, Léa Hamel Sénécal, et al.
Journal of Clinical Psychopharmacology (2017) Vol. 38, Iss. 1, pp. 94-96
Closed Access | Times Cited: 9
The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS)—Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP)
Barbara Loi, Michelle A. Sahai, Maria Antonietta De Luca, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 8
Hair Analysis of Methoxphenidine in a Forensic Chemsex Case
Ruben Goncalves, Nadège Castaing, Karine Titier, et al.
Journal of Analytical Toxicology (2021) Vol. 46, Iss. 3, pp. 328-336
Closed Access | Times Cited: 8
Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain
Kwang‐Hyun Hur, Seong‐Eon Kim, Shi‐Xun Ma, et al.
British Journal of Pharmacology (2021) Vol. 178, Iss. 19, pp. 3869-3887
Open Access | Times Cited: 8
Methoxphenidine Use Disorder
William Champeau, Céline Eiden, Julien Gambier, et al.
Journal of Clinical Psychopharmacology (2017) Vol. 37, Iss. 3, pp. 376-377
Closed Access | Times Cited: 8
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder
Matteo Caloro, Giuseppa Calabrò, Eleonora De Pisa, et al.
Journal of Addiction Medicine (2018) Vol. 12, Iss. 3, pp. 247-251
Open Access | Times Cited: 8
Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network
Céline Eiden, Sarah Leone‐Burgos, Anaïs Serre, et al.
Fundamental and Clinical Pharmacology (2018) Vol. 32, Iss. 6, pp. 654-662
Closed Access | Times Cited: 8
Diphenidine: a dissociative NPS makes an entrance on the drug scene
Maria Katselou, Ioannis Papoutsis, Panagiota Nikolaou, et al.
Forensic Toxicology (2018) Vol. 36, Iss. 2, pp. 233-242
Closed Access | Times Cited: 7
Syntheses and analytical characterizations of the research chemical 1‐[1‐(2‐fluorophenyl)‐2‐phenylethyl]pyrrolidine (fluorolintane) and five of its isomers
Michael Dybek, Jason Wallach, Pierce V. Kavanagh, et al.
Drug Testing and Analysis (2019) Vol. 11, Iss. 8, pp. 1144-1161
Open Access | Times Cited: 7
How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe
Raquel Santos‐Toscano, Amira Guirguis, Colin Davidson
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 3, pp. 452-481
Open Access | Times Cited: 7

Scroll to top